JM 010

Drug Profile

JM 010

Alternative Names: AV-2860; JM-010

Latest Information Update: 03 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Contera Pharma
  • Developer Bukwang Pharmaceutical; Contera Pharma
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Dopamine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Drug-induced dyskinesia

Most Recent Events

  • 03 Aug 2017 JM 010 is still in phase II clinical development for Drug-induced dyskinesia in South Africa (Contera Pharma website, August 2017)
  • 01 Jan 2016 Contera Pharma completes a phase II trial in Drug-induced dyskinesia in South Africa (NCT02439203)
  • 01 May 2015 Phase-II clinical trials in Drug-induced dyskinesia in South Africa (unspecified route) (NCT02439203)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top